CONMED Corporation reported a strong fourth quarter in 2025 with sales increasing by 7.9% year-over-year to $373.2 million and adjusted diluted net earnings per share rising to $1.43. The company highlighted steady execution and progress on operational initiatives, particularly in minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.

Conmed's Q1 2025 performance showed a revenue increase to $321.3 million, driven by strong constant currency growth. Adjusted diluted EPS saw a significant increase compared to the prior year, despite a decrease in GAAP EPS.

CONMED Corporation announced solid sales and earnings growth for the fourth quarter and full-year 2024, with Q4 sales increasing 5.8% to $345.9 million and adjusted diluted EPS rising 26.4% to $1.34, despite persistent supply challenges.

CONMED Corporation reported its third quarter 2024 financial results, with sales increasing by 4.0% year-over-year to $316.7 million. The company's GAAP diluted net earnings per share was $1.57, and adjusted diluted net earnings per share was $1.05, a 16.7% increase compared to the third quarter of 2023.

CONMED Corporation reported its second quarter 2024 financial results, noting that the quarter played out largely as expected but the company has not yet fully recovered from supply chain challenges, delaying commercial reacceleration. The full-year revenue guidance was revised to $1.305 billion to $1.315 billion, and adjusted diluted net earnings per share are now expected to be in the range of $3.95 to $4.02.

CONMED Corporation reported solid financial results for the first quarter ended March 31, 2024, with expected top- and bottom-line growth and margin expansion. Full-year reported revenue is now expected to be between $1.330 billion and $1.355 billion, and adjusted diluted net earnings per share are expected to be in the range of $4.25 to $4.35.

CONMED Corporation reported strong financial results for Q4 2023, achieving record revenue for both the quarter and the full year. The company's balanced growth across various businesses and geographies demonstrates the strength of its portfolio. Looking ahead to 2024, CONMED is focused on delivering innovative technology solutions in General Surgery and Orthopedics.

CONMED Corporation reported strong third-quarter results, with double-digit revenue and earnings growth. The company has updated its full-year revenue guidance to between $1.240 billion and $1.260 billion and adjusted diluted net earnings per share to a range of $3.45 to $3.55.

CONMED Corporation reported strong growth in both Orthopedics and General Surgery for the second quarter of 2023. The company is raising its revenue guidance for the full year 2023 and now expects revenue between $1.230 billion and $1.260 billion. The Company now expects full-year 2023 adjusted diluted net earnings per share in the range of $3.40 to $3.55.

CONMED Corporation announced strong first-quarter results for 2023, leading to an increased full-year revenue and adjusted diluted net earnings per share outlook. The company is raising its revenue guidance for the full year 2023 and now expects revenue between $1.205 billion and $1.250 billion, compared to its prior guidance of between $1.170 billion and $1.220 billion. The Company now expects full-year 2023 adjusted diluted net earnings per share in the range of $3.30 to $3.50, compared to its prior range of $3.20 to $3.45.

CONMED Corporation's Q4 2022 sales were negatively impacted by the implementation of new warehouse management software. Sales decreased by 8.4% year-over-year as reported, and 7.0% in constant currency. Diluted net earnings per share (GAAP) increased by 14.7%, while adjusted diluted net earnings per share decreased by 60.7%.

CONMED Corporation announced its Q3 2022 financial results, reporting strong top-line growth. The company narrowed its revenue guidance for the full year 2022 and now expects revenue between $1.1 billion and $1.115 billion. The Company now expects full-year 2022 adjusted diluted net earnings per share in the range of $3.21 to $3.28.

CONMED Corporation reported an 8.6% year-over-year increase in sales, reaching $277.2 million for the second quarter of 2022. However, the company experienced a diluted net loss per share of $5.65, compared to a net earnings per share of $0.41 in the same quarter of the previous year. Adjusted diluted net earnings per share were $0.76, a 7.0% increase year over year. The company has lowered its full-year revenue guidance due to changes in foreign exchange rates.

CONMED Corporation reported a 4.1% year-over-year increase in sales, reaching $242.3 million in Q1 2022. Diluted net earnings per share (GAAP) increased by 51.6% to $0.47, and adjusted diluted net earnings per share increased by 11.1% to $0.70.

CONMED Corporation announced its fourth quarter and full-year 2021 financial results, with the company exceeding $1 billion in annual revenue.

CONMED Corporation announced its third quarter financial results, highlighting revenue growth compared to the third quarters of 2020 and 2019, despite facing a challenging macro environment. The company is now targeting the lower end of its previously issued full-year 2021 revenue guidance and expects full-year 2021 adjusted diluted net earnings per share to be in the range of $3.18 to $3.23.

CONMED Corporation announced solid second quarter results, driven by the strong commitment and exceptional performance of their global team. The company is increasing its guidance for the full year 2021 and now expects revenue between $1.015 billion and $1.035 billion.

CONMED Corporation announced positive first-quarter results, driven by the team's perseverance in a challenging environment. The company is increasing its full-year 2021 revenue guidance to between $1.0 billion and $1.03 billion and adjusted diluted net earnings per share to a range of $3.05 to $3.20.

CONMED Corporation reported their Q4 2020 financial results, highlighting the resilience of their team in a challenging operating environment due to the ongoing impacts of COVID-19 on surgical procedure volumes.

CONMED Corporation reported its third quarter results, highlighting the team's commitment to operational execution despite ongoing geographic variability in procedure volumes due to the COVID-19 pandemic. The company remains confident in achieving profitable above-market growth over the long term.

CONMED Corporation reported financial results for the second quarter ended June 30, 2020, with management noting month-over-month improvements in revenue, profitability, and cash flow despite continued uncertainty from the COVID-19 crisis.

CONMED Corporation announced its first quarter 2020 financial results, which were meaningfully impacted by the global COVID-19 pandemic. The company has withdrawn its previously provided 2020 guidance due to the uncertainty created by this evolving dynamic.

CONMED Corporation reported its Q4 2019 earnings, highlighting the introduction of innovative new products and the successful integration of the Buffalo Filter acquisition. The company increased its investment in its sales organization during the quarter, strengthening its foundation for revenue and profitability growth.